BioXcel Therapeutics, Inc.
BTAI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,266 | $1,380 | $375 | $0 |
| % Growth | 64.2% | 268% | – | – |
| Cost of Goods Sold | $2,143 | $1,260 | $20 | $297 |
| Gross Profit | $123 | $120 | $355 | -$297 |
| % Margin | 5.4% | 8.7% | 94.7% | – |
| R&D Expenses | $30,435 | $84,326 | $91,239 | $51,589 |
| G&A Expenses | $33,103 | $63,514 | $55,755 | $0 |
| SG&A Expenses | $34,492 | $83,413 | $68,761 | $54,009 |
| Sales & Mktg Exp. | $1,389 | $19,899 | $13,006 | $0 |
| Other Operating Expenses | $2,441 | $4,163 | $0 | $0 |
| Operating Expenses | $67,368 | $171,902 | $160,000 | $105,598 |
| Operating Income | -$67,245 | -$171,782 | -$159,645 | -$105,895 |
| % Margin | -2,967.6% | -12,448% | -42,572% | – |
| Other Income/Exp. Net | $7,646 | -$7,271 | -$6,112 | -$1,398 |
| Pre-Tax Income | -$59,599 | -$179,053 | -$165,757 | -$107,293 |
| Tax Expense | $0 | $0 | $0 | -$362 |
| Net Income | -$59,599 | -$179,053 | -$165,757 | -$106,931 |
| % Margin | -2,630.1% | -12,974.9% | -44,201.9% | – |
| EPS | -23.51 | -98.35 | -94.67 | -64.87 |
| % Growth | 76.1% | -3.9% | -45.9% | – |
| EPS Diluted | -23.51 | -98.35 | -94.67 | -64.87 |
| Weighted Avg Shares Out | 2,535 | 1,821 | 1,751 | 1,648 |
| Weighted Avg Shares Out Dil | 2,535 | 1,821 | 1,751 | 1,648 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,602 | $5,649 | $2,528 | $4 |
| Interest Expense | $15,129 | $13,314 | $8,213 | $40 |
| Depreciation & Amortization | $309 | $318 | $327 | $297 |
| EBITDA | -$44,161 | -$165,421 | -$157,217 | -$106,996 |
| % Margin | -1,948.9% | -11,987% | -41,924.5% | – |